Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques
Open Access
- 15 July 2013
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 87 (14), 7805-7815
- https://doi.org/10.1128/jvi.03481-12
Abstract
To support the licensure of a new and safer vaccine to protect people against smallpox, a monkeypox model of infection in cynomolgus macaques, which simulates smallpox in humans, was used to evaluate two vaccines, Acam2000 and Imvamune, for protection against disease. Animals vaccinated with a single immunization of Imvamune were not protected completely from severe and/or lethal infection, whereas those receiving either a prime and boost of Imvamune or a single immunization with Acam2000 were protected completely. Additional parameters, including clinical observations, radiographs, viral load in blood, throat swabs, and selected tissues, vaccinia virus-specific antibody responses, immunophenotyping, extracellular cytokine levels, and histopathology were assessed. There was no significant difference ( P > 0.05) between the levels of neutralizing antibody in animals vaccinated with a single immunization of Acam2000 (132 U/ml) and the prime-boost Imvamune regime (69 U/ml) prior to challenge with monkeypox virus. After challenge, there was evidence of viral excretion from the throats of 2 of 6 animals in the prime-boost Imvamune group, whereas there was no confirmation of excreted live virus in the Acam2000 group. This evaluation of different human smallpox vaccines in cynomolgus macaques helps to provide information about optimal vaccine strategies in the absence of human challenge studies.Keywords
This publication has 47 references indexed in Scilit:
- Whither monkeypox vaccinationVaccine, 2011
- Multivalent Smallpox DNA Vaccine Delivered by Intradermal Electroporation Drives Protective Immunity in Nonhuman Primates Against Lethal Monkeypox ChallengeThe Journal of Infectious Diseases, 2011
- Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeysVaccine, 2010
- A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challengeVaccine, 2010
- Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of CongoProceedings of the National Academy of Sciences of the United States of America, 2010
- A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®Vaccine, 2010
- Vaccinia virus vaccines: Past, present and futureAntiviral Research, 2009
- Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit modelVaccine, 2009
- Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246Antimicrobial Agents and Chemotherapy, 2009
- Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challengeVaccine, 2007